Department of Surgery, Stanford University, Stanford, California.
Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston.
JAMA Surg. 2024 Nov 1;159(11):1308-1315. doi: 10.1001/jamasurg.2024.3365.
Necrotizing soft tissue infections (NSTIs) are severe life- and limb-threatening infections with high rates of morbidity and mortality. Unfortunately, there has been minimal improvement in outcomes over time.
NSTIs are characterized by their heterogeneity in microbiology, risk factors, and anatomical involvement. They often present with nonspecific symptoms, leading to a high rate of delayed diagnosis. Laboratory values and imaging help increase suspicion for NSTI, though ultimately, the diagnosis is clinical. Surgical exploration is warranted when there is high suspicion for NSTI, even if the diagnosis is uncertain. Thus, it is acceptable to have a certain rate of negative exploration. Immediate empirical broad-spectrum antibiotics, further tailored based on tissue culture results, are essential and should be continued at least until surgical debridement is complete and the patient shows signs of clinical improvement. Additional research is needed to determine optimal antibiotic duration. Early surgical debridement is crucial for improved outcomes and should be performed as soon as possible, ideally within 6 hours of presentation. Subsequent debridements should be performed every 12 to 24 hours until the patient is showing signs of clinical improvement and there is no additional necrotic tissue within the wound. There are insufficient data to support the routine use of adjunct treatments such as hyperbaric oxygen therapy and intravenous immunoglobulin. However, clinicians should be aware of multiple ongoing efforts to develop more robust diagnostic and treatment strategies.
Given the poor outcomes associated with NSTIs, a review of clinically relevant evidence and guidelines is warranted. This review discusses diagnostic and treatment approaches to NSTI while highlighting future directions and promising developments in NSTI management.
坏死性软组织感染(NSTI)是一种严重的危及生命和肢体的感染,发病率和死亡率都很高。不幸的是,随着时间的推移,其结果几乎没有改善。
NSTI 的特点是其在微生物学、危险因素和解剖学受累方面存在异质性。它们通常表现出非特异性症状,导致诊断延迟率很高。实验室值和影像学有助于增加对 NSTI 的怀疑,但最终诊断是临床诊断。当高度怀疑 NSTI 时,需要进行手术探查,即使诊断不确定也是如此。因此,存在一定的阴性探查率是可以接受的。即使诊断不确定,也应立即给予经验性广谱抗生素治疗,根据组织培养结果进一步调整,这是必不可少的,并且应至少持续到手术清创完成且患者出现临床改善迹象为止。需要进一步研究以确定最佳抗生素持续时间。早期手术清创对于改善预后至关重要,应尽快进行,理想情况下在出现症状后 6 小时内进行。随后应每 12 至 24 小时进行一次清创,直到患者出现临床改善迹象且伤口内没有其他坏死组织。没有足够的数据支持常规使用辅助治疗方法,如高压氧治疗和静脉注射免疫球蛋白。然而,临床医生应该了解正在进行的多项努力,以开发更强大的诊断和治疗策略。
鉴于 NSTI 相关的不良预后,有必要对临床相关证据和指南进行审查。本综述讨论了 NSTI 的诊断和治疗方法,同时强调了 NSTI 管理的未来方向和有前途的发展。